Ceapro Inc. to Present at the Virtual Investor Fireside Chat Series
June 09, 2020 09:00 ET
|
Ceapro Inc.
EDMONTON, Alberta, June 09, 2020 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...
Ceapro Inc. Reports 2020 First Quarter Financial Results and Highlights
May 28, 2020 09:05 ET
|
Ceapro Inc.
– Maintained production operations during COVID-19 pandemic crisis, providing our customers essential products while ensuring the health and safety of our employees – – R&D activities focused on...
Ceapro Inc. Expands Collaborative Research Program with McMaster University to Develop Inhalable Therapeutic for COVID-19
May 26, 2020 08:35 ET
|
Ceapro Inc.
– New project seeks to expand on positive preliminary results from ongoing research program with McMaster University to develop innovative drug delivery systems using disruptive PGX Technology –...
Ceapro Inc. Reports Fourth Quarter and Full Year 2019 Results and Highlights
April 16, 2020 09:00 ET
|
Ceapro Inc.
EDMONTON, Alberta, April 16, 2020 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO, OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...
Ceapro Inc. to Present at the April 2020 Virtual Investor Summit
April 15, 2020 07:35 ET
|
Ceapro Inc.
EDMONTON, Alberta, April 15, 2020 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...
Ceapro Inc. Receives Research License from Health Canada Controlled Substances and Cannabis Branch
February 14, 2020 08:00 ET
|
Ceapro Inc.
EDMONTON, Alberta, Feb. 14, 2020 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...
Ceapro Inc. to Present at Noble Capital Markets’ 16th Annual Investor Conference
February 10, 2020 08:47 ET
|
Ceapro Inc.
EDMONTON, Alberta, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...
Ceapro Inc. Announces Approval from Health Canada for Protocol Expansion of Current Clinical Study Assessing Beta Glucan as a Cholesterol-Lowering Agent
February 05, 2020 08:05 ET
|
Ceapro Inc.
– Ongoing clinical study evaluating the well-known health claims of beta glucan and its potentially beneficial approach for patients to lower plasma cholesterol – – Amendment to existing protocol...
Ceapro Inc. Secures DTC Eligibility for Publicly Traded Shares Under Ticker OTCQZ: CRPOF
January 31, 2020 09:00 ET
|
Ceapro Inc.
EDMONTON, Alberta, Jan. 31, 2020 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...
Ceapro Announces Grant of Stock Options and Restricted Share Units
January 06, 2020 09:00 ET
|
Ceapro Inc.
EDMONTON, Alberta, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of...